Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Icotrokinra→

Icotrokinra Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2763602-16-8
Molecular formula
C90H120N20O22S2
Molecular weight
1898.19 g/mol
Drug class
Interleukin-23 receptor (IL-23R) antagonistoral peptide immunomodulator
Mechanism of action
Selectively binds the IL-23 receptor and antagonises IL-23 binding, inhibiting IL-23/IL-23R-dependent release of pro-inflammatory cytokines involved in plaque psoriasis pathogenesis.
Indications / reported uses
  • Treatment of moderate-to-severe plaque psoriasis in adults and paediatric patients aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy under the US FDA ICOTYDE indication (approved 17 March 2026); the hydrochloride form is a salt of the same active peptide.

Sources: NLM DailyMed — ICOTYDE (icotrokinra) prescribing information · FDA Drug Trials Snapshot — ICOTYDE · MHRA — Icotrokinra approval, 23 October 2026 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Icotrokinra Environmental Risk Assessment (ERA) (the Icotrokinra ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.